AMGN - Amgen

-

$undefined

N/A

(N/A)

Amgen NasdaqGS:AMGN Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Location: One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, United States | Website: https://www.amgen.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

201B

Cash

8.81B

Avg Qtr Burn

N/A

Short % of Float

2.68%

Insider Ownership

0.22%

Institutional Own.

83.59%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

KRYSTEXXA Details
Chronic refractory gout

Approved

Quarterly sales

BLINCYTO® (blinatumomab) Details
B-cell acute lymphoblastic leukemia

Approved

Quarterly sales

BLINCYTO® (blinatumomab) Details
B-cell acute lymphoblastic leukemia

Approved

Quarterly sales

Approved

Quarterly sales

LUMAKRAS® (sotorasib) + Vectibix® (panitumumab) Details
Colorectal cancer , Cancer, Metastatic colorectal cancer

Approved

Quarterly sales

TEPEZZA Details
Thyroid Eye Disease , Eye disease

Approved

Quarterly sales

TAVNEOS (Avacopan) (C5aR) Details
ANCA-Associated Vasculitis, Autoimmune disease

Approved

Quarterly sales

IMDELLTRA (Tarlatamab) (AMG 757) Details
Lung cancer, Cancer, Small cell lung cancer

Approved

Quarterly sales

IMDELLTRA (Tarlatamab) (AMG 757) Details
Cancer, Lung Cancer, Small cell lung cancer

Phase 3

Data readout

Olpasiran (AMG 890) Details
Atherosclerotic cardiovascular disease

Phase 3

Data readout

Phase 3

Data readout

UPLIZNA (Inebilizumab-cdon) Details
Neuromuscular disease, Myasthenia gravis

Phase 3

Data readout

Nplate® Details
Chemo-induced thrombocytopenia

Phase 3

Data readout

TEZSPIRE Details
Chronic rhinosinusitis with nasal polyps

Phase 3

Data readout

Rocatinlimab Details
Atopic dermatitis

Phase 3

Data readout

LUMAKRAS® (sotorasib) Details
Non-small cell lung carcinoma

Phase 3

Data readout

TAVNEOS (Avacopan) (C5aR) Details
Skin disease/disorder, Hidradenitis suppurativa

Phase 3

Update

Phase 3

Update

Phase 3

Initiation

Phase 3

Initiation

Fipaxalparant (AMG 670) (HZN-825) Details
Idiopathic pulmonary fibrosis

Phase 2b

Data readout

Phase 2

Data readout

Phase 2

Data readout

UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details
Kidney transplantation, Kidney disease

Phase 2

Data readout

Phase 2

Data readout

Dazodalibep (HZN-4920) Details
Kidney disease, Lupus nephritis, Autoimmune disease

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Update

TAVNEOS (Avacopan) (C5aR) Details
Kidney disease, C3 Glomerulopathy

Phase 2

Update

Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details
Arthritis, Congenital adrenal hyperplasia, Genetic disorder, Autoimmune disease, Rheumatoid arthritis

Phase 2

Update

Tezspire Details
Chronic obstructive pulmonary disease

Phase 2a

Update

Phase 1b

Data readout

IMDELLTRA (Tarlatamab) (AMG 757) + PD-L1 inhibitor Details
Small cell lung cancer, Lung cancer, Cancer

Phase 1b

Update

HZN-457 Details
Chronic refractory gout

Phase 1

Data readout

AMG 193 Details
Cancer, Solid tumor/s

Phase 1

Data readout

Xaluritamig Details
Cancer, Castration-resistant prostate cancer

Phase 1

Data readout

Phase 1

Update